carmofur

02/01/2000 - "In the second study of patients operated at 7 Centers in the Tokai district between October 1, 1987 and September 30, 1990, 173 patients with colorectal cancer were allocated to two groups after surgery, a control group receiving no HCFU, the other group receiving HCFU at 0.8 mg/kg per day orally, for 1 year, beginning 4 weeks after the operation. "
10/01/1996 - "Tokai HCFU Study Group--third study on colorectal cancer."
03/01/2001 - "This finding suggests the promising clinical application of oral HCFU for colorectal cancer after curative resection."
10/01/1997 - "The Dukes B and C patients with colorectal cancer classified by macroscopic examination who had an intravenous MMC 6 mg/m2 on the day of operation and followed by oral HCFU for 12 months from 2 weeks after operation (Group X) were compared with patients who had operation only (Group Y). "
03/01/1986 - "The clinical response of HCFU administered orally was then evaluated in patients with colorectal cancer. "

07/01/1987 - "HCFU treatment improved the survival rate of the tumor-bearing mice. "
01/01/2021 - "A study of in vivo anticancer activity in A549 tumor-bearing nude mice shows that the tumor inhibition rate (TIR) of 5-FU@AICRM is up to ≈86.2%, 31.6% higher than that of group without green light irradiation and 20.7% higher than that of carmofur (CF, a hydrophobic analog of 5-FU)-loaded AICRM (CF@AICRM), in which CF is released slowly under light irradiation because of its hydrophobicity. "
10/01/1997 - "In a trial comparing MMC plus oral HCFU with MMC alone, a survival benefit was reported in the combined treatment group; however, the stages of cancer were unevenly distributed among the treatment groups. "
05/01/1994 - "In the first study by the "Kinki Head and Neck Tumor Study Group," we performed a comparative study to investigate intergroup difference between a control group consisting of patients given radical treatment only, and a HCFU group consisting of patients receiving long-term administration of HCFU after radical treatment. "
02/16/2022 - "In particular, the anticancer ability test showed that the HBS-DDS could be efficiently ingested by tumor cells, and its half-maximal inhibitory concentration (IC50 = 3.53 μg mL-1) for HeLa cells was close to that of free HCFU (IC50 = 5.54 μg mL-1). "

02/01/1996 - "These results suggested the long-term administration of HCFU was effective for noncuratively resected and unresected gastric cancer."
02/01/1996 - "To evaluate the efficacy of adjuvant immunochemotherapy, especially the long-term administration of HCFU to patients with noncuratively resected and unresected gastric cancer, a randomized controlled study was conducted by 16 institutions in Hokkaido. "
07/01/1996 - "[Study on the combined preoperative treatment with CDDP and HCFU for gastric cancer]."
06/01/2001 - "[Inhibition of HCFU absorption after resection for gastric cancer--application of hydroxyaluminium gel]."
02/01/1986 - "From the results, it is suggested that carmofur maintenance therapy is effective for the prevention of postsurgical recurrence of stomach cancer by means of the prolongation of patient survival."

03/01/2001 - "An animal experimental study was performed to clarify the preventive effect of oral HCFU (1-hexylcarbamoyl-5-fluorouracil) on hepatic metastasis. "
12/12/2017 - "Cell viability, apoptosis, colony formation, migration, invasion, and the expressions of cell growth- and metastasis-associated factors were respectively assessed following 0-1 µg/mL of HCFU treatment for 0-48 h. "
01/01/2006 - "First, S-1 was effective even though this patient had a lung metastasis during adjuvant treatment with HCFU. "
02/01/2000 - "The effectiveness of HCFU in reducing the disease-free survival rate appeared to be mainly due to its preventive effect on distant metastases."
02/01/1989 - "To our knowledge, there has been only one report pertaining to the efficacy of HCFU for treatment of metastatic lung lesion of HCC, so we reported a case of HCC with lung metastasis which responded to chemotherapy with a single use of HCFU. "

09/01/2005 - "We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS). "
09/01/2005 - "This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers."
10/01/1997 - "The above results suggest that HCFU is useful for patients with a high risk of recurrence who had advanced colon cancer (stage III b + IV). "
08/01/2001 - "As a result, it was suggested that oral adjuvant chemotherapy with HCFU would be effective in colon cancer patients when the duration of administration exceeded 330 days. "
09/01/2005 - "Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. "